Mobidiag Receives Second Tranche of €25M Financing from European Investment Bank
Mobidiag Ltd. (or the “Company”), a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has received the second tranche of €10M from the €25M growth capital loan signed with the European Investment Bank Group (EIB) in May 2019. These new funds will be used to advance Mobidiag’s research and development and facilitate further validation and commercialisation of new molecular diagnostics tests using the Company’s Amplidiag® and Novodiag® platforms.
The loan is supported by the European Fund for Strategic Investments (EFSI) , the main pillar of Investment Plan for Europe , through the European Growth Finance Facility (EGFF) initiative. This is the second operation between Mobidiag and EIB, following the first loan in 2016 for €15M.
Tuomas Tenkanen, CEO of Mobidiag, commented, "Thanks to the EIB’s continued support and endorsement of our strategy, Mobidiag has developed an extensive portfolio of innovative diagnostic solutions for gastrointestinal and respiratory infections, such as COVID-19, healthcare associated infections and antimicrobial resistance management. The continued adoption for routine use of our Amplidiag® and Novodiag® platforms by key laboratories throughout Europe means that we are constantly working to ramp up our manufacturing capacities in order to meet this growing demand.
The EIB has contributed significantly to the growth of Mobidiag since 2016 and this second loan is invaluable in helping us to facilitate our rapid growth, enabling us to become a key player in the diagnostics market.”
Notes to editors
About Mobidiag Ltd
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose fast, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
About the EIB
The European Investment Bank (EIB) is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investment in order to contribute towards EU policy goals. The EIB helps the economy, create jobs, promote equality and improve lives for EU citizens and for people in developing countries.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PROCAD30.10.2020 17:33:11 CET | Press release
Code:n@xt: PROCAD to Lift the Veil on a New PLM Generation
CA-ANDERSEN-GLOBAL30.10.2020 14:55:04 CET | Pressemeddelelse
Andersen Global udvider sin dækning til Skt. Kitts og Nevis
NY-INX-LIMITED30.10.2020 14:02:12 CET | Press release
INX Applies for Listing on the Canadian Securities Exchange (CSE)
CA-VERACYTE,-INC.30.10.2020 13:17:09 CET | Press release
Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance
COUNTERPOINT-RESEARCH30.10.2020 12:57:08 CET | Press release
Global Smartphone Market Shows Signs of Recovery in Q3
URBAN-2030.10.2020 11:07:09 CET | Press release
On the Occasion of UN World Cities Day, Urban 20 (U20) Engagement Group of the G20, Announces the Creation of a “Global Urban Resilience Fund” in Response to COVID-19
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom